1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med, 2015, 372(9): 793-795.
2. World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization, 2017: 23. http://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf.
3. Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis, 2018, 18(1): 76-84.
4. Walzl G, Mcnerney R, du Plessis N, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis, 2018, 18(7): e199-e210.
5. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014: 11. http://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf?sequence=1.
6. World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. Geneva: World Health Organization, 2016. http://www.who.int/tb/WHOPolicyStatementSLLPA.pdf.
7. Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis, 2018, 18(7): e183-e198.
8. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. Geneva: World Health Organization, 2016. http://apps.who.int/iris/bitstream/handle/10665/250125/9789241549639-eng.pdf;sequence=1.
9. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization, 2018. http://apps.who.int/iris/ bitstream/handle/10665/260494/9789241550079-eng.pdf?sequence=1.
10. 唐神结, 李亮, 高文, 等. 中国结核病年鉴2017. 北京: 人民卫生出版社, 2018.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med, 2001, 345(15): 1098-1104.
12. Koo MS, Manca C, Yang G, et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One, 2011, 6(2): e17091.
13. Tsenova L, O’brien P, Holloway J, et al. Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis. J Interferon Cytokine Res, 2014, 34(9): 716-726.
14. Oehlers SH, Cronan MR, Scott NR, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature, 2015, 517(7536): 612-615.
15. Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci USA, 2015, 112(6): 1827-1832.
16. Mily A, Rekha RS, Kamal SM, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS One, 2015, 10(9): e0138340.
17. Coussens AK, Wilkinson RJ, Hanifa YA, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA, 2012, 109(38): 15449-15454.
18. Salahuddin N, Ali F, Hasan Z, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonar. BMC Infect Dis, 2013, 13(1): 22.
19. Schiebler M, Brown K, Hegyi K, et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med, 2015, 7(2): 127-139.
20. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 2015, 385(9977): 1511-1518.
21. Remmelts HF, Meijvis SA, Biesma DH, et al. Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia. Clin Vaccine Immunol, 2012, 19(9): 1532-1538.
22. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res, 2005, 6(1): 82.
23. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med, 2006, 34(4): 1080-1086.
24. Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci, 2015, 11(3): 584-590.
25. Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med, 2014, 2(2): 108-122.
26. Joshi L, Chelluri LK, Gaddam S. Mesenchymal stromal cell therapy in MDR/XDR tuberculosis: a concise review. Arch Immunol Ther Exp (Warsz), 2015, 63(6): 427-433.
27. 张立群, 唐神结. 纳米技术在结核病中的应用研究及其进展. 中华结核和呼吸杂志, 2016, 39(5): 393-395.
28. Mukherjee B. Nanosize drug delivery system. Curr Pharm Biotechnol, 2013, 14(15): 1221.
29. Coler RN, Bertholet S, Pine SO, et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis, 2013, 207(8): 1242-1252.
30. Dhanasooraj D, Kumar RA, Mundayoor S. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles. Int J Nanomedicine, 2013, 8: 835-843.
31. Feng G, Jiang Q, Xia M, et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One, 2013, 8(4): e61135.
32. Gaspar DP, Faria V, Gonçalves LM, et al. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies. Int J Pharm, 2016, 497(1/2): 199-209.
33. Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis, 2017, 17(1): 39-49.
34. Lee RE, Hurdle JG, Liu J, et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med, 2014, 20(2): 152-158.
结核病精准治疗的现状与未来[D]. 1. 同济大学附属上海市肺科医院结核病临床研究中心 上海市结核病（肺）重点实验室（上海 200433）; 2. 首都医科大学附属北京胸科医院结核病多学科诊疗中心 北京市结核病胸部肿瘤研究所（北京 101149）, 2018.
结核病精准治疗的现状与未来. Diss. 1. 同济大学附属上海市肺科医院结核病临床研究中心 上海市结核病（肺）重点实验室（上海 200433）; 2. 首都医科大学附属北京胸科医院结核病多学科诊疗中心 北京市结核病胸部肿瘤研究所（北京 101149）, 2018.
(2018). 结核病精准治疗的现状与未来. (Doctoral dissertation, 1. 同济大学附属上海市肺科医院结核病临床研究中心 上海市结核病（肺）重点实验室（上海 200433）; 2. 首都医科大学附属北京胸科医院结核病多学科诊疗中心 北京市结核病胸部肿瘤研究所（北京 101149）).